3-D Matrix, Ltd.

Equities

7777

JP3410730000

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
119 ^JPY	+0.85%		+3.48%	-15.00%

Apr. 04	3-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc.	CI
Mar. 19	3-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc.	CI

3-D Matrix, Ltd. signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd.

August 02, 2021

3-D Matrix, Ltd. (JASDAQ:7777) signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd. on August 3, 2021. As part of the transaction, 3-D Matrix, Ltd. will transfer patent and license to PURMX Therapeutics Co., Ltd.

Latest news about 3-D Matrix, Ltd.

3-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc.	Apr. 03	CI
3-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc.	Mar. 18	CI
3-D Matrix, Ltd.(TSE:7777) dropped from S&P Global BMI Index	23-09-18	CI
3-D Matrix, Ltd. announced that it has received ¥686.237876 million in funding from CVI Investments, Inc.	23-07-17	CI
3-D Matrix, Ltd. announced that it expects to receive ¥686.237876 million in funding from CVI Investments, Inc.	23-06-28	CI
3-D Matrix, Ltd. announced that it has received Â¥508.76 million in funding from CVI Investments, Inc.	23-03-15	CI
3-D Matrix, Ltd. announced that it expects to receive ¥508.76 million in funding from CVI Investments, Inc.	23-02-27	CI
3-D Matrix, Ltd. announced that it has received ¥2.059835568 billion in funding from CVI Investments, Inc.	22-10-16	CI
3-D Matrix, Ltd. announced that it expects to receive Ã‘2.059835568 billion in funding from CVI Investments, Inc.	22-09-29	CI
3-D Matrix, Ltd. Auditor Raises 'Going Concern' Doubt	22-07-27	CI
3-D Matrix, Ltd. announced that it has received ¥1.77192847 billion in funding from CVI Investments, Inc.	22-04-26	CI
3-D Matrix, Ltd. announced that it expects to receive ¥1.77192847 billion in funding from CVI Investments, Inc.	22-04-10	CI
3-D Matrix, Ltd. announced that it has received ¥2.609 billion in funding from CVI Investments, Inc.	21-08-26	CI
3-D Matrix, Ltd. announced that it expects to receive ¥2.609 billion in funding from CVI Investments, Inc.	21-08-10	CI
3-D Matrix, Ltd. signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd.	21-08-02	CI
3-D Matrix, Ltd. Announces Board Appointments	21-08-02	CI
3-D Matrix, Ltd. announced that it has received ¥216.0702 million in funding from CVI Investments, Inc.	20-11-25	CI
3-D Matrix, Ltd. announced that it expects to receive ¥216.0702 million in funding from CVI Investments, Inc.	20-11-09	CI
3-D Matrix, Ltd. announced that it has received ¥12.8 million in funding from CVI Investments, Inc.	20-01-09	CI
3-D Matrix, Ltd. announced that it expects to receive ¥12.8 million in funding from CVI Investments, Inc.	19-12-19	CI
3-D Matrix, Ltd. announced that it has received ¥1.31202 billion in funding from CVI Investments, Inc.	19-04-14	CI
3-D Matrix, Ltd. announced that it expects to receive ¥1.31202 billion in funding from CVI Investments, Inc.	19-03-28	CI
3-D Matrix, Ltd. announced that it has received ¥17.055 million in funding from SMBC Nikko Securities Inc., Investment Arm	18-07-16	CI
3-D Matrix, Ltd. announced that it expects to receive ¥17.055 million in funding from SMBC Nikko Securities Inc., Investment Arm	18-06-27	CI
3-D Matrix, Ltd. announced that it has received ¥885.0474 million in funding	17-11-19	CI

Chart 3-D Matrix, Ltd.

Duration

Period

More charts

Company Profile

3-D Matrix, Ltd. is a company engaged in the research, development, manufacture and sale of medical products. The Company has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.

Sector

Biotechnology & Medical Research

Calendar

2024-06-10 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
3-D MATRIX, LTD.	-15.00%	60.2M
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+47.58%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research

3-D Matrix, Ltd.

Equities

7777

JP3410730000

Biotechnology & Medical Research

3-D Matrix, Ltd. signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd.

Latest news about 3-D Matrix, Ltd.

Chart 3-D Matrix, Ltd.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research